Results of a retrospective study of a racially diverse population demonstrated positive outcomes for patients with NSCLC who experience irAEs when treated with immune checkpoint inhibitors.
Chronic kidney disease is not uncommon among patients with PsA, with risk factors including diabetes and NSAID use, while methotrexate use offered protective benefits.